Successful management of methicillin-resistant Staphylococcus aureus bacteremia unresponsive to vancomycin by adding fosfomycin: A case report

Journal of the Medical Association of Thailand

Volumn 95, Issue 7, 2012, Pages 960-963

  Linasmita, Patcharasarn ^a  

^a SRINAKHARINWIROT UNIVERSITY   (Thailand)

Author keywords

Combination therapy; Fosfomycin; MRSA; Vancomycin

Indexed keywords

FOSFOMYCIN; FUSIDIC ACID; RIFAMPICIN; VANCOMYCIN;

ADULT; AORTITIS; ARTERIOVENOUS FISTULA; ARTICLE; CASE REPORT; DISK DIFFUSION; DRUG DOSE REDUCTION; EPSILOMETER TEST; ERYTHEMA; FEMALE; FEVER; HEMODIALYSIS; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYCOTIC ANEURYSM; RECOMMENDED DRUG DOSE;

ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOSFOMYCIN; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; SEPSIS; VANCOMYCIN;

EID: 84864425212     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52: 285-292.
2. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398-2402.
3. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: 193-200.
4. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52: 3315-3320.
5. Alvarez S, Jones M, Berk SL. In vitro activity of fosfomycin, alone and in combination, against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1985; 28: 689-690.
6. Grif K, Dierich MP, Pfaller K, Miglioli PA, Allerberger F. In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother 2001; 48: 209217.
7. Pistella E, Falcone M, Baiocchi P, Pompeo ME, Pierciaccante A, Penni A, et al. In vitro activity of fosfomycin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy. Infez Med 2005; 13: 97-102.
8. Dalet F, Bade G, Roda M. Pharmacokinetics of fosfomycin during hemodialysis. Chemotherapy 1977; 23 (Suppl 1): 210-216.
9. Revert L, Lopez J, Pons J, Olay T. Fosfomycin in patients subjected to periodic hemodialysis. Chemotherapy 1977; 23 (Suppl 1): 204-209.
10. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008; 46: 1069-1077.